Swiss approval for SOBI's Xiapex

16 October 2015

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for Xiapex (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease.

The indication is for patients with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.

Xiapex is also approved in Switzerland for the treatment of Dupuytren's contracture in adult patients with a palpable cord. The drug was approved by the European Commission for the treatment of Peyronie’s disease early this year (The Pharma Letter February 2, 2015). It was also approved in 2011 as a non-surgical treatment option for Dupuytren’s contracture in adult patients with a palpable cord.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK